Evidence map›Paper›PMID 34894069›Full record

ReviewJournal of cellular and molecular medicine2022

A close-up view of dynamic biomarkers in the setting of COVID-19: Striking focus on cardiovascular system.

Aysa Rezabakhsh, Seyyed-Reza Sadat-Ebrahimi, Alireza Ala, Seyed Mohammad Nabavi, Maciej Banach, Samad Ghaffari

Abstract readReview
In one paragraph

Review in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aysa RezabakhshCardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0003-3942-7848
Seyyed-Reza Sadat-EbrahimiCardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Alireza AlaEmergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, Iran.
Seyed Mohammad NabaviApplied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-8859-5675
Maciej BanachDepartment of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.
Samad GhaffariCardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the recent reports, cardiovascular events encompass a large portion of the mortality caused by the COVID-19 pandemic, which drawn cardiologists into the management of the admitted ill patients. Given that common laboratory values may provide key insights into the illness caused by the life-threatening SARS-CoV-2 virus, it would be more helpful for screening, clinical management and on-time therapeutic strategies. Commensurate with these issues, this review article aimed to discuss the dynamic changes of the common laboratory parameters during COVID-19 and their association with cardiovascular diseases. Besides, the values that changed in the early stage of the disease were considered and monitored during the recovery process. The time required for returning biomarkers to basal levels was also discussed. Finally, of particular interest, we tended to abridge the latest updates regarding the cardiovascular biomarkers as prognostic and diagnostic criteria to determine the severity of COVID-19.

Indexed as

BiomarkersCardiovascular DiseasesCardiovascular SystemChemokine CCL2COVID-19Creatine Kinase, MB FormFibrin Fibrinogen Degradation ProductsHomocysteineHumansInterferon-gammaInterleukin-6L-Lactate DehydrogenaseNatriuretic Peptide, BrainPeptide FragmentsPrognosisSARS-CoV-2BiomarkersCCL2 protein, humanChemokine CCL2Creatine Kinase, MB FormFibrin Fibrinogen Degradation Productsfibrin fragment DHomocysteineIFNG protein, humanIL6 protein, humanInterferon-gammaInterleukin-6L-Lactate DehydrogenaseNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Troponin ITroponin TTumor Necrosis Factor-alphacardiac biomarkerscardiovascular systemCOVID-19laboratory biomarkersSARS-CoV-2

Identifiers

PMID34894069
PMCPMC8743667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.